A comparison of 5 or 7 days of rabeprazole triple therapy for eradication of Helicobacter pylori
Aim A combination of PPI and 1000 mg amoxicillin/500 mg clarithromycin twice daily for 2 weeks has been provenÂ effective in the eradication of H. pylori. Most studies suggested that treatment for 7 and 10 days may be equallyÂ effective. Few data are available on the efficacy of 5-day triple therapy. Aim of this study was to compare 5-day andÂ 7-day rabeprazole triple therapy for eradication of H. pylori infection.
Methods We prospectively studied 60 consecutive H. pylori-infected patients who came to hospitals in six centres inÂ Indonesia and who underwent upper endoscopy and biopsy. H. pylori infection was confirmed if two rapid urease testsÂ (Pronto Dry) and histology or urea breath test were positive. Patients were assigned to either an open-labelled 5-dayÂ or 7-day course of oral amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., and rabeprazole 10 mg b.i.d. (RAC).Â Four weeks after therapy, all patients had a repeated UBT for evaluation of the presence of H. pylori.
Results Of the 60 patients (42 males and 18 females) with mean age (Â± SD) 47.63 Â± 13.93 years, range 21â€“74 years, 25Â patients (41.7%) had 5-day treatment and 35 patients (58.3%) had 7-day treatment. With 5-day treatment, 18 patientsÂ (72%) and with 7-day treatment 32 patients (91.4%) became negative for H. pylori infection. The eradication failureÂ was found on 7 patients (28.0%) in 5-day treatment and 3 patients (8.6%) in 7-day treatment.
Conclusions The study showed that the eradication of H. pylori infection by triple rabeprazole-based treatment inÂ 7-day is still better than in 5-day. (Med J Indones 2010; 19:113-7)
Keywords: H. pylori, rabeprazole, triple therapy
Copyright (c) 2010 Ari F. Syam, Murdani Abdullah, Abdul A. Rani, Siti Nurdjanah, Pangestu Adi, Ali Djumhana, Pangarapen Tarigan, I. D.N. Wibawa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.